member, Figure 1 ), the Chair of the Organizing Committee for the 2013 Annual Meeting, opened the meeting by a brief introduction and welcome to the invited guests and all attendees, Dr. Wei Zhang, the President of USCACA (Figure 2 ), gave his presidential address. He first provided an overview of the establishment of USCACA and the fast growth of this organization. He emphasized the role of USCACA in bridging close interaction of cancer researchers, clinicians, and pharmaceutical companies between the United States and China. Dr. Zhang also outlined the key initiatives and programs of USCACA, including the establishment of USCACA-NFCR-AFCR Scholar Exchange and Fellowship Program in Basic, Translational, and Clinical Studies, a highly successful partnership with NFCR and AFCR. The attendance of the presidents of NFCR and AFCR (Franklin Salisbury and Sujuan Ba) highlighted the commitment of these two major partners in the fellowship. Another important fellowship program is to sponsor the training scholars for early phase I clinical research, which was supported by Hengrui Medicine Co., Ltd.
Dr. Zhang then briefly addressed the success of CJC, the official PubMed-indexed English journal coowned by CACA and USCACA in partnership with Sun Yat-sen University Cancer Center. With this successful partnership, 32 issues have been published so far, accompanied by a quick and steady increase in citations of papers published in this professional journal of cancer research. Following the topic of CJC, Dr. Chao-Nan Qian (Figure 3) 
Drs. Wancai Yang and Yunguang Tong introduced the USCACA-TIGM Esophageal Cancer Program
Drs. Wancai Yang (USCACA Executive Committee member, Dean of the School of Basic Medical Sciences, Xinxiang Medical University) and Yunguang Tong (USCACA Executive Committee member), the principle investigators of the USCACA-TIGM awarded program for translational research of esophageal cancer prevention and treatment, reported the progress of this project.
Dr. Yang presented the scope of award and its impact, followed by introducing his team and the resources in Xinxiang Medical University where this project is homed in China ( Figure 6 ). Xinxiang Medical University is the only standing medical university in Henan, a province with a population of more than 100 million people. There are more than 40 Universityaffiliated teaching hospitals with about 66,000 in-patient beds. Dr. Yang returned to Xinxiang Medical University from University of Illinois at Chicago in 2012 and has established his Research Laboratory for Cancer Signal Transduction. The USCACA-TIGM sponsored cancer research program focuses on gastrointestinal cancers, especially esophageal cancer, the most common and deadliest disease in the area of Taihang Mountains, including Northern Henan province, China. This particular region has the highest incidence of esophageal cancer in the world. Dr. Yang's lab has banked several thousands of gastrointestinal biopsy and resected tumor tissues as well as matched blood samples. This provides a fundamental basis for translational researches of Chinese high-incident cancers, particularly esophageal cancer, among Xinxiang Medical University, USCACA, academia, and pharmaceutical industries in the United States and in China. These collaborative researches include the identification and validation of cancer type- specific biomarkers and molecular targets for cancer prevention and therapeutic interventions.
Dr. Yunguang Tong (Figure 7 ) then introduced the collaboration model between USCACA and Xinxiang Medical University. USCACA will contribute to datamining, genomic medicine, and clinical studies, and Xinxiang Medical University will perform preclinical validation and provide patient resources. Dr. Tong then updated the progresses of the project, which briefly include that 1) the research team has investigated esophageal cancer at transcriptomic, epigenetic, and genomic levels; 2) different levels of information have been integrated using integrative genomic approaches to identify biomarkers for esophageal cancer prevention and treatment; 3) a novel algorithm has been developed to prioritize candidate biomarkers; and 4) a biomarker database for esophageal cancer research has been established, and leading biomarker candidates have been found for further validation. Last, Dr. Tong introduced an ongoing project which combined data of gene methylation with gene expression in esophageal squamous cell carcinoma.
Panel discussion on translational research in oncology research & development and its implication in China Dr. Michael Shi (USCACA Executive Committee member, Senior Global Clinical Leader, Novartis), the panel discussion moderator, opened the panel discussion on the topic of USCACA and SFDA/ C e n t e r o f D r u g E v a l u a t i o n ( C D E ) P a r t n e r s h i p by introducing the background about increasing Figure 5 . Dr. Shiyuan Cheng, the newly elected P r e s i d e n t o f U S C A C A , a n n o u n c e d t h e 2 0 1 3 development plan of USCACA. The discussion focused on how to best take ethnic and genetic differences into consideration while developing new targeted therapies. Such differences are not only reflected in different drug metabolism and drug transport systems but also present as molecularly distinct cancer subtypes of the same organ origin. Targeted agent development needs to be customized to address these cancers or cancer subtypes uniquely prevalent in Asia Pacific. The discussants all agreed that closer collaboration should be centered in the following areas: 1) biomarker-adaptive clinical trial; 2) standardization of acquisition and analysis of biospecimens; 3) regulatory framework to test combinations of investigational drugs; and 4) center of excellence of clinical oncology trials in China. Dr. Zhu Chen also commented on the increasing pricing of some oncology drugs. He used the example of the deal reached last year between China healthcare providers with Novartis AG (NOVN) in which the company agreed to donate three doses of its leukemia drug Gleevec for every one sold to the government. Western drugmakers may have to trade some of the profit on expensive cancer drugs to access China's "huge market."
2013 Annual Szent-Gyorgyi Prize Ceremony of NFCR USCACA also sponsored a table at the 8th SzentGyorgyi Prize Ceremony of NFCR. This year the prestigious award went to Alex Matter, MD, CEO of the Experimental Therapeutic Centre of A*STAR in Singapore, Member of the Swiss Academy of Medical Sciences. The award recognizes his fundamental contribution in the development of Gleevec. Dr. Zhu Chen, the former Minister of Health of China, the cowinner of this prize in 2012 (with Dr. Zheng-Yi Wang) introduced Dr. Alex Matter as the "Father of Targeted Therapy" and presented Dr. Matter with the prize. The prize ceremony was attended with worldwide leaders in cancer research and therapies in both the United States and China. Ten members of the USCACA executive committee attended the ceremony and had a pleasant greeting with Dr. Zhu Chen, Dr. Alex Matter, and worldwide attendees. 
